Sign Up to like & get
recommendations!
1
Published in 2022 at "ChemCatChem"
DOI: 10.1002/cctc.202200140
Abstract: Molnupiravir (Lagevrio®) is an orally‐administered anti‐COVID‐19 agent. Due to the urgency to meet the worldwide demand and the growing environmental concern, there is a need for speed in the industrial implementation of novel and efficient…
read more here.
Keywords:
molnupiravir paving;
mediated synthesis;
synthesis;
enzyme mediated ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.2195
Abstract: Since the beginning of the COVID-19 pandemic, efforts have been made to develop new therapies for COVID19.1,2 The drugs developed in the meantime focus on completing a COVID-19 response strategy to prevent serious illness, hospitalization,…
read more here.
Keywords:
evidence new;
uncertainties evidence;
embracing uncertainties;
evidence ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Journal of Medical Virology"
DOI: 10.1002/jmv.27730
Abstract: Broad‐spectrum antiviral agents targeting viral RNA‐dependent RNA polymerase (RdRp) are expected to be a key therapeutic strategy in the ongoing coronavirus disease 2019 (COVID‐19) pandemic and its future variants of severe acute respiratory syndrome coronavirus…
read more here.
Keywords:
severe acute;
syndrome coronavirus;
coronavirus;
molnupiravir ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "Medicinal Chemistry Research"
DOI: 10.1007/s00044-021-02841-3
Abstract: During the COVID-19 pandemic, various drug candidates have been developed, molnupiravir (MK-4482 and EIDD-2801), which is a new orally anti-viral agent under development for the treatment of COVID-19, is under study in the final stage…
read more here.
Keywords:
chemistry;
molnupiravir;
treatment covid;
drug ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Toxicology and Applied Pharmacology"
DOI: 10.1016/j.taap.2022.116003
Abstract: Molnupiravir is an orally active nucleoside analog antiviral drug that recently was approved by the U.S. FDA for emergency treatment of adult patients infected with the SARS-CoV-2 (COVID-19) virus and at risk for severe progression.…
read more here.
Keywords:
molnupiravir molecular;
molnupiravir;
descriptors mitochondrial;
functional descriptors ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
2
Published in 2021 at "ACS Omega"
DOI: 10.1021/acsomega.1c00772
Abstract: Molnupiravir (MK-4482, EIDD-2801) is a promising orally bioavailable drug candidate for the treatment of COVID-19. Herein, we describe a supply-centered and chromatography-free synthesis of molnupiravir from cytidine, consisting of two steps: a selective enzymatic acylation…
read more here.
Keywords:
molnupiravir 4482;
molnupiravir;
synthesis molnupiravir;
4482 eidd ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "ACS sensors"
DOI: 10.1021/acssensors.2c00447
Abstract: Nucleoside analogues are reagents that resemble the structure of natural nucleosides and are widely applied in antiviral and anticancer therapy. Molnupiravir, a recently reported nucleoside analogue drug, has shown its inhibitory effect against SARS-CoV-2. Rapid…
read more here.
Keywords:
molnupiravir sensor;
pharmacology;
based molnupiravir;
molnupiravir ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "RSC Advances"
DOI: 10.1039/d3ra08098f
Abstract: In the present study, nanoceria-decorated MWCNTs (CeNPs@MWCNTs) were synthesized using a simple and inexpensive process. Molnupiravir (MPV) has gained considerable attention in recent years due to the infection of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).…
read more here.
Keywords:
simultaneous monitoring;
engineering carbon;
molnupiravir;
surface engineering ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "Expert Opinion on Drug Discovery"
DOI: 10.1080/17460441.2022.2153828
Abstract: ABSTRACT Introduction Molnupiravir (MOV) is a broad-spectrum oral antiviral agent approved for the treatment of COVID-19. The results from in vitro and in vivo studies suggested MOV activity against many RNA viruses such as influenza…
read more here.
Keywords:
discovery development;
preclinical discovery;
molnupiravir;
treatment ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae685
Abstract: Abstract Background We examined the clinical effectiveness of molnupiravir in reducing deaths in a real-world cohort of adult patients with COVID-19 during the Omicron outbreak. Methods This was a population-wide retrospective cohort study in the…
read more here.
Keywords:
sars cov;
molnupiravir;
mortality;
cohort study ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "Toxicological Sciences"
DOI: 10.1093/toxsci/kfae112
Abstract: Abstract Molnupiravir is registered or authorized in several countries as a 5-d oral coronavirus disease 2019 treatment for adults. Molnupiravir is a prodrug of the antiviral ribonucleoside β-D-N4-hydroxycytidine (NHC) that distributes into cells, where it…
read more here.
Keywords:
genotoxicity carcinogenicity;
carcinogenicity study;
molnupiravir;
comprehensive genotoxicity ... See more keywords